Ligand Pharmaceuticals, Inc. (LGND) Misses Q3 EPS by 5c
Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q3 EPS of ($0.01), $0.05 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $6.4 million versus the consensus estimate of $8.4 million.
Separately, the company announced it is restating LFY11, Q112, Q212 financials.
For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.
Separately, the company announced it is restating LFY11, Q112, Q212 financials.
For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.